Abstract:Here we uncover a pathological mechanism in Alzheimer's disease linking abnormal hypermetabolism of glucose in hiPSC‐derived astrocytes and neurons to an abnormal and potentially toxic glutamate accumulation. Increased glucose metabolism was found in astrocytes and neurons carrying familial Alzheimer's disease mutations. Diseased astrocytes exhibit reduced expression of the excitatory amino acid transporter 2 but increased glutamate oxidative metabolism, which supports an increased synthesis of glutamine. Glutamine uptake is increased in diseased neurons, and glutamate release is enhanced completing a potentially toxic cycle. Our findings further identify metabolic and neurotransmitter imbalances that may operate at early phases of Alzheimer's disease pathophysiology. Glutamate recycling between neurons and astrocytes is essential to maintain neurotransmitter homeostasis. Disturbances in glutamate homeostasis, resulting in excitotoxicity and neuronal death, have been described as a potential mechanism in Alzheimer's disease (AD) pathophysiology. However, glutamate neurotransmitter metabolism in different human brain cells, particularly astrocytes, has been poorly investigated at the early stages of AD. We sought to investigate glucose and glutamate metabolism in AD by employing human induced pluripotent stem cell (hiPSC)‐derived astrocytes and neurons carrying mutations in the amyloid precursor protein (APP) or presenilin‐1 (PSEN‐1) gene as found in familial types of AD (fAD). Methods such as live‐cell bioenergetics and metabolic mapping using [13C]‐enriched substrates were used to examine metabolism in the early stages of AD. Our results revealed greater glycolysis and glucose oxidative metabolism in astrocytes and neurons with APP or PSEN‐1 mutations, accompanied by an elevated glutamate synthesis compared to control WT cells. Astrocytes with APP or PSEN‐1 mutations exhibited reduced expression of the excitatory amino acid transporter 2 (EAAT2), and glutamine uptake increased in mutated neurons, with enhanced glutamate release specifically in neurons with a PSEN‐1 mutation. These results demonstrate a hypermetabolic phenotype in astrocytes with fAD mutations possibly linked to toxic glutamate accumulation. Our findings further identify metabolic imbalances that may occur in the early phases of AD pathophysiology.

Downregulation of GABA Transporter 3 (GAT3) is Associated with Deficient Oxidative GABA Metabolism in Human Induced Pluripotent Stem Cell-Derived Astrocytes in Alzheimer's Disease

Increased glucose metabolism and impaired glutamate transport in human astrocytes are potential early triggers of abnormal extracellular glutamate accumulation in hiPSC‐derived models of Alzheimer's disease

Alzheimer’s Disease Enhanced Tonic Inhibition is Correlated With Upregulated Astrocyte GABA Transporter-3/4 in a Knock-In APP Mouse Model

Single-nucleus transcriptional profiling uncovers the reprogrammed metabolism of astrocytes in Alzheimer's disease.

Impaired expression of GABA transporters in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus

Functional Metabolic Mapping Reveals Highly Active Branched-Chain Amino Acid Metabolism in Human Astrocytes, Which Is Impaired in iPSC-Derived Astrocytes in Alzheimer's Disease

Genetic Dissection of Glutathione S-transferase Omega-1: Identification of Novel Downstream Targets and Alzheimer’s Disease Pathways

Increased GABAergic development in iPSC-derived neurons from patients with sporadic Alzheimer's disease

GABA transporters gene expression associates with [18F]FDG‐PET signal in regions typically hypometabolic in Alzheimer’s disease

Deficient brain GABA metabolism leads to widespread impairments of astrocyte and oligodendrocyte function

Astrocytic proteins involved in regulation of the extracellular environment are increased in the Alzheimer's disease middle temporal gyrus

Global Metabolic Shifts in Age and Alzheimer's Disease Mouse Brains Pivot at NAD+/NADH Redox Sites

Aberrant Expression of the Pore-Forming KATP Channel Subunit Kir6.2 in Hippocampal Reactive Astrocytes in the 3Xtg-Ad Mouse Model and Human Alzheimer's Disease.

[P3–170]: HUMAN IPSC‐DERIVED ALZHEIMER's DISEASE ASTROCYTES RECAPITULATE DISEASE‐RELATED PHENOTYPES

Reduced uptake of [11C]‐ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer’s dementia

Reduction of Astrocytic Glutamate Transporter Contributes to Amyloid-induced phagocytosis

Scavenging Reactive Oxygen Species Decreases Amyloid- Levels via Activation of PI3K/Akt/GLUT1 Pathway in N2a/APP695swe Cells

Inhibition of the mitochondrial pyruvate carrier in astrocytes reduces amyloid and tau accumulation in the 3xTgAD mouse model of Alzheimer's disease

Morphological and Molecular Alterations of Reactive Astrocytes Without Proliferation in Cerebral Cortex of an APP/PS1 Transgenic Mouse Model and Alzheimer's Patients

Upregulated excitatory amino acid transporter 1 (EAAT1) expression in the human medial temporal lobe in Alzheimer's disease

Multi-omics Reveals Changes in Astrocyte Fatty Acid Metabolism During Early Stages of Alzheimer's Disease